United States Authorizes AstraZeneca COVID Drug For Few Vulnerable

Posted by: Kyeyune Andrew Jonathan in World news December 9, 2021

United States health authorities on Wednesday authorities the use of Synthetic antibodies developed by AstraZeneca to prevent COVID-19 infections.

However, they will majorly use this on people who react badly to the vaccines

This is the first time the Food and Drug Administration in United States has given emergency authorization for such a purely preventative treatment.

The FDA however, warned the drug Evulshed is “not a substitute for vaccination in individuals for whom they recommend vaccination”. It said they can only authorize the drug for people with weak immune systems or those who cannot get the vaccine for medical reasons.

In these cases such as allergic reactions, they can administer the drug to people of 12 years and above.

Evulshed combines two types of synthetic antibodies (tixagevimab and cilgavimab), and is given as two intramuscular injections.

These antibodies help the immune system fight off the virus by targeting its spike protein. This allows it to enter cells and infect them.

The FDA said the treatment may be effective for pre-exposure prevention for six months. However, they cannot administer it to someone who is already Covid positive.

The side effects listed include allergic reaction, bleeding from the injected area, headache, and fatigue. The FDA authorized the drug after clinical trials on people older than 59, or with a chronic disease registered success.

3500 people received the drug while 1,700 received a placebo. The trial showed that the treatment cut the risk of developing COVID-19 by 77%.

Check Also;

This is not a Paywall, but Newslex Point's journalism consumes a lot of time, hard-work and money. That's why we're kindly requesting you to support us in anyway they can, for as little as $1 or more, you can support us .

Please use the button below to contribute to Newslex Point, Inc. using a credit card or via PayPal.